SOUTH SAN FRANCISCO, Calif., April 22, 2025 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (UNITY) [NASDAQ:UBX], a biotechnology company developing therapeutics to slow, halt, or reverse diseases of aging, today reported financial results for the first quarter ended March 31, 2025.

Originally posted here:
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial Results and Business Updates

Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science Poster Presentations featuring the latest advancements on anti-TROP2 ADCs (OBI 992 and OBI 902), AKR1C3 prodrug (OBI-3424), OBI’s novel ADC enabling technologies (GlycOBI® and ThiOBI®), and Globo H science

See the article here:
OBI Pharma Announces Poster Presentations at the AACR 2025 Annual Meeting for OBI-992 and OBI-902 Antibody-Drug Conjugates (ADCs), GlycOBI® and...

Basel, 23 April 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the introduction of its innovative Chest Pain Triage algorithm as part of the navify? Algorithm Suite. This groundbreaking algorithm is designed to more quickly and accurately detect Acute Coronary Syndrome (ACS) in patients presenting with chest pain, one of the most common reasons for Emergency Department (ED) visits. As EDs are typically one of the most crowded hospital units, leading to challenges to swiftly diagnose critical conditions, such as chest pain.4 This new algorithm was developed in collaboration with Universitätsklinikum Heidelberg.

See the article here:
Roche receives CE Mark for its Chest Pain Triage algorithm to enhance detection of Acute Coronary Syndrome (ACS)

ZURICH, SWITZERLAND, and BROOKLYN, NEW YORK, USA, April 23, 2025 -- VERAXA Biotech AG (“VERAXA” or the “Company”), an emerging leader in designing novel cancer therapies, and Voyager Acquisition Corp., a Cayman Islands exempted company and special purpose acquisition company targeting the healthcare sector (NASDAQ: VACH, “Voyager” or the “SPAC”), announced today that they have entered into a definitive business combination agreement (the "Business Combination Agreement"). The proposed business combination (the "Business Combination") would create a publicly traded, clinical-stage biopharmaceutical company focused on the development of a comprehensive pipeline of next-generation cancer therapies. Upon closing of the transaction, VERAXA Biotech AG is expected to list on NASDAQ under the proposed ticker symbol “VERX.”

Continue reading here:
VERAXA Biotech and Voyager Acquisition Corp. Announce Business Combination Agreement to Create Nasdaq-Listed Biopharmaceutical Company Advancing a...

Five abstracts accepted for poster presentations

View original post here:
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025

Japans big bet on stem-cell therapies might soon pay off with medical breakthroughs  Nature

The rest is here:
Japans big bet on stem-cell therapies might soon pay off with medical breakthroughs - Nature

The Future of Medicine: Japan Forges Ahead in iPS Cell Research  nippon.com

Excerpt from:
The Future of Medicine: Japan Forges Ahead in iPS Cell Research - nippon.com

Pioneering a Cure for Parkinson's Disease: First Allogeneic iPS Cell-Based Therapy Demonstrates Safety and Efficacy  cira.kyoto-u.ac.jp

More:
Pioneering a Cure for Parkinson's Disease: First Allogeneic iPS Cell-Based Therapy Demonstrates Safety and Efficacy - cira.kyoto-u.ac.jp

Dont rush promising stem-cell therapies  Nature

See the article here:
Dont rush promising stem-cell therapies - Nature

Clinical trials test the safety of stem-cell therapy for Parkinsons disease  Nature

Read more:
Clinical trials test the safety of stem-cell therapy for Parkinsons disease - Nature

Kyoto University Team Achieves Breakthrough In Parkinson's Treatment  Evrim Aac

Read the original:
Kyoto University Team Achieves Breakthrough In Parkinson's Treatment - Evrim Aac

Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem cell transplantation (AHSCT)  Nature

View original post here:
Narsoplimab for refractory transplantation-associated thrombotic microangiopathy (TA-TMA) in adult patients receiving allogeneic hematopoietic stem...

What are stem cells and why are they a lifesaving cure for blood cancer?  India Today

Excerpt from:
What are stem cells and why are they a lifesaving cure for blood cancer? - India Today

Stem Cell Therapies Could Treat Parkinson's Disease by Rebuilding Lost Circuitry in the Brain, Studies Suggest  Smithsonian Magazine

Read the rest here:
Stem Cell Therapies Could Treat Parkinson's Disease by Rebuilding Lost Circuitry in the Brain, Studies Suggest - Smithsonian Magazine

Autologous Versus Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Knee Osteoarthritis: A Systematic Review, Pairwise and Network Meta-Analysis of Randomized Controlled Trials  Cureus

Original post:
Autologous Versus Allogeneic Adipose-Derived Mesenchymal Stem Cell Therapy for Knee Osteoarthritis: A Systematic Review, Pairwise and Network...

Exploring the mechanism of bone marrow mesenchymal stromal cell exosomes in respiratory syncytial virus infection based on miRNA sequencing  Nature

Read more here:
Exploring the mechanism of bone marrow mesenchymal stromal cell exosomes in respiratory syncytial virus infection based on miRNA sequencing - Nature

hBMEC altered CD34 expression in HSPC. HSPC were irradiated (2, 4 Gy...  ResearchGate

Read more here:
hBMEC altered CD34 expression in HSPC. HSPC were irradiated (2, 4 Gy... - ResearchGate

April 11, 2025

Link:
Preliminary Results for the Year Ended 31 December 2024

NAPLES, Fla. and CAMBRIDGE, United Kingdom, April 11, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) ("Conduit Pharmaceuticals" or "Conduit" or the “Company”) today announces the filing of two groundbreaking patents for tapinarof (VTAMA®), including a dual active cocrystal, pairing the drug currently approved in the US for psoriasis and atopic dermatitis with a complementary drug substance known to address key patient needs in inflammatory skin conditions. The Company anticipates this combination drug approach could offer enhanced patient benefits over existing tapinarof formulations by addressing both therapeutic needs and known side effects, such as pain and itch, which are a known priority to sufferers of these conditions but typically overlooked by standard treatments that focus on the underlying disease alone.

Visit link:
Conduit Pharmaceuticals Announces Novel Cocrystal Patent Filing For VTAMA® (tapinarof) with Enhanced Therapeutic and Market Extension Prospects

PALO ALTO, Calif., April 11, 2025 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it will effect a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-35, to be effective as of 12:01 a.m. Eastern Time on April 15, 2025.

Continued here:
Scilex Holding Company Announces 1-for-35 Reverse Stock Split